Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell said the group is "poised to deliver against a number of key milestones this year" as she highlighted phase I trial results from AT278 as potentially pivotal.
Top-line data is expected sometime in the first half for Arecor's concentrated, rapid-acting insulin, which Howell believes could disrupt the market.
This is because it would provide the "critical enabler" in the development of miniaturised and longer-wear insulin delivery systems.
Her comments accompanied full-year results from the drug developer, a report that not only provided an update on the financial health of the business but also chronicled a busy year operationally.
Chief among the highlights was the the launch of Arecor's first commercial product incorporating Arestat in late 2023 which is now generating royalties under a worldwide license agreement.
Howell called this "significant" and "a clear validation of the potential of the Arestat platform".
"We have also continued to further strengthen our partnered portfolio and licensed programmes and have seen continued traction with the European roll-out of Ogluo," she added.
Revenues from Ogluo hit £2.9 million in the year, up from £1.1 million. Overall, turnover grew by 90% in the 12 months ended December 31 to £4.6 million. Arecor posted a loss of £8.6 million as it invested in R&D and its product roll-out. More importantly, it exited the period with cash of £6.8 million.